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PREDICTIVE VALUE OF PRE-LEUKAPHERESIS CD34 CELL LEVELS
AND THE EFFICIENCY OF COLLECTION OF PERIPHERAL BLOOD STEM
CELLS USING HIGH-VOLUME LEUKAPHERESIS
G.J. O’Neill, J. Gouvea, K. McCoy, J. Steinberg, S. Bell, D. Gomer, 
S. Carpenter, D. Maharaj
Bone Marrow/Stem Cell Transplant Institute of Florida, Fort Laud-
erdale, FL
Although CD34 cell counts from peripheral blood have been shown to be useful in
predicting whether stem cell mobilization will result in the collection of sufﬁcient cells
for transplantation, it remains difﬁcult to estimate the number of leukaphereses required
to obtain such levels. Here, we examine the relationship between the pre-leukapheresis
CD34 cell levels from peripheral blood and the efﬁciency of the leukapheresis proce-
dure in 30 oncology patients (16 breast, 2 ovarian, and 12 hematological malignancies)
with a total of 102 leukapheresis products using the Cobe Spectra (COBE BCT, Lake-
wood, CO). Peripheral blood stem cells were mobilized with chemotherapy followed by
G-CSF (5 u/kg/day) with a target value for transplant of 1107 CD34 cells/kg collect-
ed from each patient. Samples for CD34 estimation (per L) were taken before leuka-
pheresis, at 2 hours during the procedure (approximately 6–8 L processed) and from the
ﬁnal product (approximately 25–30 L processed). When these CD 34 cell counts were
compared, a strong correlation was found between the pre-leukapheresis CD34 cell
count and those obtained at both 2 hours (r  0.90) and from the ﬁnal product (r 
0.98). On the other hand, no correlation was found between the ﬁnal CD34 cell count
of the product and either the pre-leukapheresis WBC, MNC count, or platelet count of
the patient. Similarly, no correlation was found between CD34 cell counts and the
hematocrit of the ﬁnal product. In spite of the strong correlation between pre-CD34
cell counts and those of the ﬁnal product, it remains difﬁcult to predict with accuracy
the number of leukapheresis procedures to reach the required CD34 cell target for
transplant. To examine this further, we investgated the ﬁeld of each leukapheresis pro-
cedure by dividing the actual CD34 cell count of the product by the theoretical value
obtained from the pre-CD34 cell count from the peripheral blood expressed as a per-
centage. The mean overall efﬁciency of collection for all leukaphereses was 39% (medi-
an 37%) and no correlation between the efﬁciency of the collection and the pre-CD34
cell count was observed. When the pheresis collections were divided into 3 groups,
however, according to pre-CD34 cell counts (Gp 1  0.02 to 0.19%; Gp 2  0.20 to
0.99%; Gp 3  1% and above), the efﬁciency of collection in both Group 2 (44%) and
Group 3 (49%) was signiﬁcantly lower than that of Group 1 (25%) patients (p  0.05).
In these 3 leukapheresis groups, the median number of procedures to reach a target of
1107 CD34+ cells for tranaplant was 0.45 for Gp 3 (12 L processed), 1.0 for Gp 2
(25 L processed) and 4.5 for Gp 1 (112 L processed). Therefore, although
pre-leukapheresis CD34+ cell counts appear to be useful predictors for stem cell leuka-
pheresis transplant targets, other factors inﬂuencing the yield efﬁciency of these proce-
dures must be further investigated to reliably determine the number of procedures to be
carried out in these patients.
ALLOGENEIC IMMUNITY CAN BE A DECISIVE FACTOR IN RESTORING
A COMPLETE REMISSION IN ACUTE LEUKEMIA PATIENTS FAILING
CHEMOTHERAPY AND BONE MARROW TRANSPLANTATION
Arnold D. Rubin, Hamdy Mohtaseb, Gerry Rubin, Dennis Todd
St. Joseph’s Hospital and Medical Center, Paterson, NJ
Last year we reported on 2 patients with relapsed AML after allo-
geneic bone marrow transplantation (BMT) and treated with G-
CSF stimulated leukocyte donor infusions (DLI). The ﬁrst patient
expired from meningeal leukemia with a marrow in complete
remission (CR). The second patient required cytotoxic chemother-
apy before DLI to establish a CR containing 100% donor cells.
We now extend these studies and describe 4 more relevant patients.
The second patient went on to relapse in 6 months but a CR was
restored after repeating chemotherapy and DLI followed by main-
tenance with daily IL-2. A third patient relapsed following BMT
from an unrelated donor and died in a pancytopenic phase despite
chemotherapy and DLI. A fourth patient with CML in blast crisis
relapsed following a related BMT. Chemotherapy and DLI
restored a 100% donor CR, and the patient is well and recovered
from hepatic GVHD and a systemic CMV infection. A ﬁfth patient
relapsed 3 months after a BMT from a mismatched relative. Cessa-
tion of cyclosporine restored CR despite a treatable bout of pul-
monary GVHD. A sixth patient aged 64 with a Ph chromosome
hybrid ALL/AML in third relapse was treated with subablative
doses of chemotherapy before the ﬁrst exposure to G-CSF–stimu-
lated sibling leukocytes. He achieved a CR engrafted with donor
cells. We conclude that it is possible to utilize adoptive allogeneic
immunity as a decisive form of treatment of acute leukemia. Fur-
thermore, it may not appear necessary to expose patients to life
threatening myeloablative regimens to eliminate the leukemic
clones and establish a functioning bone marrow chimera. Thus
BMT as a definitive treatment for some malignancies may be
extended to a much larger proportion of the population.
DOUBLE CLASS II MICROMISMATCHES INCREASE THE RISK OF ACUTE
GRAFT-VS.-HOST DISEASE AFTER UNRELATED DONOR MARROW
TRANSPLANTATION WITH TACROLIMUS AND MINIMETHOTREXATE
FOR PROPHYLAXIS
D. Przepiorka, C. Ippoliti, I. Khouri, K. Cleary, H. Fischer, H. Fritsche, D.
LeBherz, N. Ueno, R. Mehra, S. Giralt, J. Gajewski, M. Donato, 
D. Claxton, I. Braunschweig, B. Andersson, P. Anderlini, R. Champlin
University of Texas, MD Anderson Cancer Center, Houston, TX
Randomized studies have demonstrated that tacrolimus is more
effective than cyclosporine for the prevention of GVHD after
MUD BMT. We reviewed our experience using tacrolimus for
MUD BMT to determine the effect of micromismatches on out-
come. Eighty adults of median age 34 years with hematologic
malignancies received a myeloablative regimen and an unmanipu-
lated marrow transplant from an unrelated donor serologically
matched for HLA-A, HLA-B, and HLA-DRB1. Molecular class II
typing was performed by sequence-specific primer polymerase
chain reaction. Fifty-four patient-donor pairs were molecularly
matched for HLA-DRB1 and HLA-DQB1; 14 had a molecular
mismatch at either locus and 12 had a micromismatch at both loci.
Tacrolimus was administered at 0.03 mg/kg/day i.v. CI, and doses
were adjusted to maintain whole blood IMx levels of 5–15 mg/mL.
MTX 5 mg/m2 was given on days 1, 3, 6, and 11. Patients with
GVHD that persisted despite high-dose steroids for 48 hours
were considered refractory. The actuarial risk of Gr 2–4 GVHD
was 42% in the matched, 46% in the 1 mismatch, and 71% in the 2
mismatches group. Gr 3–4 GVHD occurred in 16, 27, and 60%,
respectively. Refractory GVHD occurred in 20, 23, and 60% of
patients, respectively. Only the patients with mismatches in both
HLA-DRB1 and HLA-DQB1 had a significant increase in
GVHD. Tacrolimus and miniMTX is not effective GVHD pro-
phylaxis with a double class II molecular mismatch.
TRANSPLANTATION OF LEUKEMIA PATIENTS RECEIVING HIGH DOSE
CHEMOTHERAPY WITH EX VIVO EXPANDED CORD BLOOD CELLS
E.J. Shpall, R. Briddell, L. Hami, A. Gringeri, R. Jones, S. Bearman, P. Cag-
noni, R. Quinones, R. Giller, Y. Nieto, S. Roman-Unfer, M. Ross, I. McNiece
BMT Program, University of Colorado Health Sciences Center, Denver,
CO
Cord blood (CB) cells are being used increasingly as a source of hematopoi-
etic cells to support high-dose chemotherapy (HDC). However, CB units
contain low numbers of cells, including CD34 cells and GM-CFC, and their
use is associated with signiﬁcant delays in engraftment of both neutrophils
and platelets. We developed culture conditions which resulted in expansion of
cells (100-fold) and GM-CFC (20- to 80-fold). In the present studies, we have
evaluated the engraftment potential of expanded CB. Patients (n3) were
treated with HDC-melphalan (140 mg/m2), TBI (1200 cGy), and ATG (90
mg/kg). On day 0 of transplant, CB from an unrelated donor, which was sup-
plied by the New York Placental/Cord Blood Program, was thawed and 60%
of the CB product was infused without manipulation. The CD34 cells in the
remaining 40% of the product were isolated with the Baxter Isolex 300i
device and expanded in teﬂon bags in 1 L of deﬁned media containing 100
ng/mL each of rhSCF, rhG-CSF, and rhMGDF. After 10 days in culture at
37°C in 5% CO2, the cultured product was harvested, washed to remove
media and growth factors, and reinfused into the patients. Table 1 summa-
rizes the expansion and engraftment data for these patients. 
WT Infused cells (107/kg) Expansion of Engraftment
Patient # (kg) Day 0 Day 10 CFC (fold) ANC PLTS
1 116 0.35 0.09 26 34 62+
2 74 0.4 0.29 10 21 36+
3 86 0.37 0.31 40 26 26+
Reinfusion of the expanded cells was not associated with any adverse events.
Neutrophil engraftment (days to ANC 500/uL) occurred on days 34, 21, and
26, respectively, while all 3 patients still remain platelet transfusion dependent.
Previous studies by Gluckman and colleagues reported that for patients greater
than 45 kg in weight, only 11 of 23 and 5 of 23 achieved neutrophil and
platelet engraftment by day 60, respectively. This suggests that expanded CB
cells may provide more rapid engraftment in larger patients. The study contin-
ues to accrue patients and a second cohort will be enrolled using CB banked in
aliquots to enable thawing and expansion at day 10 to enable reinfusion of
both the expanded and unmanipulated fractions on day 0.
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CORRELATION OF CIRCULATING CD4 CELL COUNTS WITH RISK OF
OPPORTUNISTIC INFECTION POST-BMT
T. Small, E. Papadopoulos, F. Boulad, D. George, N. Kernan, 
P. Szabolcs, B. Childs, H. Castro-Malaspina, A. Jacubowski, J. Young,
R.J. 0’Reilly
Memorial Sloan Kettering Cancer Center, New York, NY
In patients with AIDS, the risk of developing an AIDS-deﬁning
opportunistic infection (CMV, PCP, fungal, toxoplasmosis, atypi-
cal mycobacteria, EBV-LPD) correlates with patient CD4 cell
counts, thus allowing the rational formulation of antimicrobial pro-
phylaxis and treatment regimens to prevent these infections based
on an individual’s CD4 count. To determine whether CD4 counts
post-BMT correlate with the risk of developing these same oppor-
tunistic infections, the CD4 counts and infectious complications of
281 consecutive durably engrafted patients after related T cell-
depleted or any type of unrelated transplant were evaluated. Some
(36%) engrafted patients developed an opportunistic infection,
with 94% occurring 0.8–6.1 months post-BMT. Patients with
CD4 cell counts 200 cells/uL 1.5–4 months posttransplant had a
signiﬁcantly increased risk of developing an opportunistic infec-
tion. While greater than 65% of patients with CD4 cell counts of
50 cells developed an opportunistic infection, less than 15% with
counts 200 cells did so (p  0.05). Patient PHA response, CD3,
or CD8 cell counts did not correlate with infection risk. This data
suggests that tailoring the duration and intensity of antimicrobial
therapy to the duration and severity of CD4 lymphopenia might
decrease the incidence of posttransplant opportunistic infections as
has been possible in patients with AIDS.
COLLECTION, TUMOR CONTAMINATION, AND ENGRAFTMENT KINET-
ICS OF HIGHLY PURIFIED HEMATOPOIETIC PROGENITOR CELLS TO
SUPPORT HIGH-DOSE THERAPY IN MULTIPLE MYELOMA
G. Tricot, Y. Gazitt, T. Leemhuis, S. Jagannath, K.R. Desikan, 
D. Siegel, A. Fassas, S. Tindle, J. Nelson, C. Juttner, A. Tsukamoto, 
J. Hallagan, K. Atkinson, C. Reading, R. Hoffman, B. Barlogie
Greenebaum Cancer Center, University of Maryland, Baltimore, MD
Unfractionated PBSCs contain 0.1–1% of myeloma cells. In con-
trast, FACS-sorted CD34Thy1Lin-cells are substantially
enriched for stem cell activity, yet contain virtually no clonal
myeloma cells. A study was performed in myeloma patients with
12 months of preceding chemotherapy to evaluate large scale
puriﬁcation of stem cells and study engraftment kinetics and tumor
cell contamination, based on PCR for CDR III. PBSC were mobi-
lized with cyclophosphamide and GM-CSF. Elutriation and chem-
ical lysis were used to debulk PBSC collections. Subsequently,
CD34Thy1Lin-cells were puriﬁed with high-speed cell sorting.
Of the 10 evaluable patients, 9 met the required minimum criteria
of 	7.2105cells/kg for tandem transplants. After high-dose mel-
phalan (200 mg/m2), eight patients engrafted successfully even
though granulocyte (ANC 0.5109/L; 16 days) and platelet
recovery (platelets 50109/L; 39 days) were delayed. Three
patients proceeded to a second graft after high-dose melphalan and
total-body irradiation. Two required infusion of a reserve graft;
one showed delayed but complete engraftment. Two of the 9
patients attained a complete remission. The grafts from 3 patients
were tested for tumor contamination and contained no detectable
clonal myeloma cells. Larger quantities of puriﬁed cells may be
required to resolve the problem of delayed engraftment.
DOSE-ESCALATED TOTAL-BODY IRRADIATION (TBI) AND AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) FOR
CHEMOTHERAPY REFRACTORY LYMPHOMA
T.R. Spitzer, S.L. McAfee, R. Sackstein, C. Colby, S. Powell
Massachusetts General Hospital, Boston, MA
Bone marrow transplant preparative regimens using high-dose (1200
cGy) TBI are associated with reduced risk of relapse but increased regimen-
related morbidity and mortality. Based on data from previous TBI dose-esca-
lation trials, the maximally tolerated dose (MTD) of TBI has been consid-
ered to be 1600 cGy. To maximize tumor cell kill with acceptable toxicity,
we have undertaken a phase I-II trial of dose-escalated TBI with autologous
PBSCT for chemotherapy refractory lymphoma. Three intended dose levels
of fractionated TBI (200 cGy twice daily) have been chosen: 1600 cGy, 1800
cGy, and 2000 cGy. Lung blocks with electron boosts to reduce TBI trans-
mission dose by 50% are used. Shielding of the kidneys is performed to keep
the maximal renal dose at 1600 cGy. Eight patients have received dose-esca-
lated TBI & PBSCT. Three patients (two with non-Hodgkin’s lymphoma
(NHL) in resistant relapse (RR), one with primary refractory (PR) Hodg-
kin’s disease (HD) received 1600 cGy  PBSCT. Three patients (2 NHL in
RR, I PRHD) received 1800 cGy  PBSCT. Two patients with NHL (one
in RR, one with PR disease) received 2000 cGy  PBSCT. Autologous bone
marrow was infused with PBSC in two patients who had insufﬁcient num-
bers of CD 34 peripheral blood cells. Median (range) days to ANC 	0.5
and plts 	20 K were 12 (9–13) and 14 (9–122) days, respectively. Three
patients have achieved a CR (16, 32, 12 months) and two a PR (8,1
months). No life-threatening toxicities have occurred. No patient has had
evidence of hepatic veno-occlusive disease. Seven of eight patients required
narcotic analgesics for grade II mucositis-related pain. One patient who
received 1800 cGy developed interstitial pneumonitis after receiving recom-
binant alpha-interferon (with exacerbation following re-challenge with IFN).
Neurologic toxicities have consisted of a symmetrical upper or lower extrem-
ity sensory neuropathy (n3) and Lhermitte’s syndrome (nl). One patient
who received 1600 to 2000 cGy developed protracted anorexia, fatigue, and
myalgias requiring low-dose corticosteroids. TBI in a dose range of 2000
cGy as preparative therapy for autologous PBSCT is feasible and has sub-
stantial activity (3 CR, 2 PR among 8 patients) in refractory non-Hodgkin’s
and Hodgkin’s lymphoma.
REMISSION OF RED CELL APLASIA (RCA) FOLLOWING AN AUTOLO-
GOUS TRANSPLANT (AT) FOR LYMPHOMA
Neil Weiner, Arthur Rabinowitz, James Sparks, David Steinberg
Lahey Hitchcock Clinic, Burlington, MA
RCA, an autoimmune blood dyscrasia, occurs in chronic lympho-
cytic leukemia (CLL) and responds to immunosuppressive agents.
Myeloablative chemotherapy is profoundly immunosuppressive
and some patients with autoimmune disorders have improved fol-
lowing allogeneic and autologous transplants. We report a 57-year-
old female with Richter’s transformation of CLL and RCA in
whom erythroid recovery occurred following an AT. The patient
was diagnosed with CLL (Rai stage 0) in July 1990. She required
no therapy for 7 years. In January 1997, splenomegaly, anemia, and
thrombocytopenia developed. Bone marrow biopsy revealed CLL,
clusters of large cell lymphoma (LCL), and dysplastic erythroid
precursors. She was treated with CHOP and after 4 cycles, LCL
was no longer detected in the marrow. Residual CLL and absent
erythroid precursors were noted. She became transfusion-depen-
dent and prednisone was started without effect. An additional cycle
of CHOP was administered and during marrow recovery 2.99106
peripheral CD34 cells/kg were collected. Subsequently, she
underwent AT after high-dose cyclophosphamide, BCNU, and
etoposide (CBV). Bone marrow biopsy on day 63 documented nor-
mal erythroid precursors and no evidence of CLL or LCL. AT has
been effective in patients with refractory immune thrombocy-
topenic purpura (Blood 88 (Suppl 1):133a, 1996). The result in our
patient, if sustained, suggests that AT may also be useful in RCA
associated with CLL.
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EX VIVO EXPANSION AND ACTIVATION OF PERIPHERAL BLOOD T
LYMPHOCYTES FOR CANCER IMMUNOTHERAPY USING IL-2, IL-12,
AND ANTI-CD3
Amal Abu-Ghosh, Carina Torres, John Qian, Carmella van de Ven,
Mitchell S. Cairo
Children’s Hospital of Orange County, Orange, CA
Cytotoxic T lymphocytes are increasingly being considered as a form of
cancer immunotherapy against a variety of malignant tumors. We have stud-
ied the ex vivo generation, expansion, and activation of cytotoxic T lymho-
cytes (CD8, CD4Th1) from adult peripheral blood mononuclear cells
(PBMNC) using a combination of IL-2, IL-12, and anti-CD3. Lymphokines
and monoclonal antibodies were added to PBMNC cultures in AIM-5
serum-free medium at the following concentrations: IL-2 (100 U/mL), IL-12
(100 U/mL) and anti-CD3 (50 ng/mL) for group 1 (G1) and the same
anti-CD3 and IL-2 concentrations but lower IL-12 concentration (5 U/mL)
for group 2 (G2). Day 7 cultures showed signiﬁcant increase in total cell
expansion of 6.4-fold 
 0.46 (mean 
 SEM) for G1 and 7.3-fold 
 0.3 for
G2 compared with controls (C) (0 and 0.6 
 0.6 for G1 and G2, respectively,
p  0.05). CD3 cells were signiﬁcantly increased in G1 vs. C (97.4 
 0.1%
vs. 90.8 
 1.3%, p  0.05), and G2 vs. C (97.2 
 13% vs. 82.1 
 9.2%, p 
0.05). CD8 cells were also signiﬁcantly increased in G1 vs. C (70.96 
 3.14
vs. 29.1 
 3.8%, p  0.05) and in G2 vs. C (58.0 
 0.13% vs. 17.4 
 0.14%,
p  0.0001). T cell activation markers measured by ﬂow cytometry were
increased in both groups; HLA-DR was signiﬁcantly increased in G1 and
G2 compared with controls (G1, 34 
 12.3 vs. 4.7 
 0.92%, p  0.05; G2,
20.5 
 6.2% vs. 6.29 
 2.9%, p  0.05). IL-2R expression was also signiﬁ-
cantly increased for G1 and G2 compared with respective controls (G1, 38.9

 14.4 vs. 0.57 
 0.18%, p  0.05; G2, 13.24 
 5.8 vs. 0.26 
 0.0%, p 
0.05). In summary, we were able to generate a CD3-enriched T lymphocyte
population with increased cytotoxic CD8 T cells and increased expression of
activation cell surface markers (HLA-DR and IL-2R) by expanding
PBMNC with IL-2, IL-12, and anti-CD3 in vitro. Future ex vivo studies are
under way to determine the optimal concentrations to expand and activate
cytotoxic T lymphocytes for adoptive cancer immunotherapy.
INCREASED RISK OF CHRONIC GVHD IN ALLOGENEIC PERIPHERAL
BLOOD STEM CELL TRANSPLANTATION COMPARED TO BONE MARROW
Önder Arslan, Haluk Koç, Hamdi Akan, Meral Beksaç, Osman Ilhan,
Günhan Gürman, Muhit Özcan, Celalettin Üstün, Nahide Konuk,
Akin Uysal
Ibni Sina Hospital, BMT Unit, Ankara, Turkey
Allogeneic peripheral blood stem cell transplantation (alloPBSCT)
from HLA-identical siblings was performed in 22 patients with acute
nonlymphoblastic leukemia (11) and chronic myelogenous leukemia
(11). Outcomes were compared with a historical group of 62 patients
with similar variables (patient and donor age, sex mismatch, donor
parity, phase of disease, time to transplant, conditioning regimen, and
graft-vs.-host disease [GVHD] prophylaxis) receiving bone marrow
(alloBMT) from HLA-identical donors. Median time to reach neu-
trophil count 0.5109/L and platelet count 20109/L occurred
on days 13.5 and 12.5 in patients receiving alloPBSCT and days 17
and 21 in patiens transplanted with bone marrow (p  0.05). AlloPB-
SCT group required a median of 2 U of red blood cells and 16 U of
platelets compared with 5 U of red blood cells and 48 U of platelets
for patients receiving bone marrow (p  0.05). Overall aGVHD inci-
dence was similar in both groups (42 vs. 40%, p  0.05). The inci-
dence of grade II–IV aGVHD was 42% in alloPBSCT compared
with 35% in alloBMT patients (p  0.05). cGVHD of all grades
developed in 10 of 13 (77%) in the alloPBSCT group and 11 out of
53 (21%) in the alloBMT recipients (p  0.002). Day 200 transplant-
related mortality was 18% (4/22) in the alloPBSCT group and 23%
(14/62) in the alloBMT patients (p  0.05). Twenty-seven (44%)
patients in the alloBMT group and ﬁve (23%) in the alloPBSCT
group died. Seventeen (77%) PBSC and 35 (56%) bone marrow
recipients are still alive and disease-free. In conclusion, this retrospec-
tive comparison suggests that compared with bone marrow, alloPB-
SCT from HLA-identical donors is associated with faster engraft-
ment, fewer transfusions, and no greater incidence of aGVHD but
with high incidence of cGVHD.
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
ACUTE NONLYMPHOBLASTIC LEUKEMIA
Önder Arslan, Haluk Koç, Hamdi Akan, Meral Beksaç, Osman Ilhan,
Günhan Gürman, Muhit Özcan, Nahide Konuk, Akin Uysal
Ibni Sina Hospital, BMT Unit, Ankara, Turkey
Unmodiﬁed allogeneic peripheral blood stem cell transplantation
(alloPBSCT) was performed in 20 consecutive acute nonlym-
phoblastic leukemia (ANLL) patients from their HLA-identical
siblings There were 11 male and 9 female patients. Median age was
34 years (range 17–43). Donors were primed with 2.5–5 g/kg/day
s.c. granulocyte colony-stimulating factor (G-CSF, Neupogen,
Roche). Conditioning regimen was Bu (16 mg/kg) plus Cy (120
mg/kg) in 19 patients and high-dose Ara-C (3 g/m2 twice daily  3
days) for the patient who relapsed after bone marrow transplanta-
tion. All except the relapsed patient were in CR1. CsA plus short-
term MTX (n=19) or CsA alone (n=1) were used for GVHD pro-
phylaxis. Median number of apheresis procedures for each patient
was 2 (2–4). A median of 6.5 (3.2–38.2)108/kg MNC or 9.4
(2.2–12.4)106/kg CD34 cells were given. Median days to reach
granulocyte of 0.5109/L and platelet of 50109/L were 12
(10–14) and 15 (11–35), respectively. Day 100 transplant-related
mortality was 20% (4/20). Grade II–IV aGVHD was seen in 8 of
17 (47%) evaluable patients; severe aGVHD occurred in 3 of 17
(18%). Clinical cGVHD of all grades developed in 11 of 15 (73%)
evaluable patients. Median follow-up is 504 (75–743) days. None of
the patients relapsed within 12 months after the procedure. In con-
clusion, alloPBSCT in ANLL is associated with a faster engraft-
ment, no greater incidence of aGVHD but an increased risk of
cGVHD, which may translate into low risk of relapse within the
ﬁrst year after transplant.
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
STANDARD-RISK LEUKEMIAS
Haluk Koç, Önder Arslan, Günhan Gürman, Celalettin Üstün, Muhit
Özcan, Imdat Dilek, Hamdi Akan, Osman Ilhan, Nahide Konuk, Akin
Uysal, Meral Beksaç
Ibni Sina Hospital, BMT Unit, Ankara, Turkey
Twenty-six patients with standard-risk leukemias who underwent
allogeneic peripheral blood stem cell transplantation (alloPBSCT)
from HLA-identical siblings were analyzed particularly for their
engraftment kinetics and the incidence and severity of GVHD.
Standard-risk leukemia was deﬁned as having ANLL or ALL in
ﬁrst complete remission or CML in ﬁrst chronic phase within the
ﬁrst year after diagnosis. Recipients had a median age of 34 years
(range 17–43). Stem cells were mobilized using 10 mcg/kg/s.c.  5
days of G-CSF (Neupogen, Roche), collecting a median of 8.6
(0.8–90)106/kg CD34 cells. A total of 62 leukaphereses were
performed for the 26 donors and the median number of apheresis
procedures was 2 (1–4). Cyclosporine-A (CsA) plus a short course
of MTX was used for GVHD prophylaxis. Engraftment times to a
granulocyte count 0.5109/L and platelets 20109/L were
achieved at a median of day 13 (range 10–18) and day 13 (range
9–33), respectively. Patients receiving 4.0106/kg CD34 cells
had signiﬁcantly accelerated granulocyte (p  0.05) and platelet (p
 0.04) engraftment compared with lower doses. Median
follow-up is 351 (95–715) days. Acute GVHD occurred in 11 of 22
(50%) evaluable patients and only 4 (18%) of them had severe dis-
ease (grade III-IV). Chronic GVHD occurred in 11 of 17 (65%)
evaluable patients. In conclusion, alloPBSCT in standard-risk
leukemias is an alternative for allogeneic bone marrow transplanta-
tion with faster hematological recovery and no increased risk of
acute GVHD. The incidence of chronic GVHD seems to be
increased with this type of treatment modality in this study and
needs further conﬁrmation with randomized trials.
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COMBINED CD34 SELECTION AND T-CELL PURGING RESULTS IN
EXTREMELY T CELL-DEPLETED BONE MARROW GRAFTS
H. Atkins, M. Halpenny, P. Birch, C. Bredeson, I. Bence-Bruckler, 
S. McDiarmid, A. Guilivi, L. Huebsch
Blood and Marrow Transplant Program, Ottawa General Hospital,
Ottawa, Ontario, Canada
Immunologically naive hematopoietic grafts may allow allogeneic
transplantation across major HLA incompatiblities or the treat-
ment of autoimmune diseases with high-dose lymphoablation and
autologous stem cell rescue. We wished to determine whether
CD34 cell selection followed by CD2 purging produces extremely
T cell-depleted grafts.
G-CSF–stimulated PBSC collections and a bone marrow graft
were obtained from 10 normal donors. T-cell depletion (TCD) by
CD34 selection was done using either the Isolex SA (Baxter, IL) or
Ceprate SC (Cellpro, WA) on each day of collection. Products
were stored at 4C. On the ﬁnal collection day, the products were
pooled for additional TCD using an anti-CD2 antibody with a
Maxsep (Baxter, IL).
The ﬁrst processing step resulted in 53 
 22% CD34 cell recovery
and 3.00 
 0.37 log TCD. The second step resulted in 74 
 16%
CD34 cell recovery and a further 1.25 
 0.45 log TCD. Overall, the
two-step procedure resulted in 47 
 32% CD34 cell recovery and a
4.46 
 0.58 log TCD. The T cell dose infused was 0.21–6.0106 T
cells/recipient. Nine grafts were infused into HLA haploidentical
recipients and acute GVHD occurred in only 2 patients (grade II
skin). All evaluable patients had primary engraftment.
In summary, sequential CD34 selection and CD2 purging results
in grafts that retain functional hematopoietic stem cells with mini-
mal T cells or immune functionality. Sequentially processed grafts
will allow the use of transplantation for innovative therapies.
IMMUNE RECONSTITUTION FOLLOWING HIGH-DOSE CHEMOTHERAPY
WITH STEM CELL RESCUE FOR ADVANCED BREAST CANCER
D. Avigan, Z. Wu, J. Gong, C. Wheeler, A. Elias, R. Joyce, P. Richardson,
G. Demetri, C. Bunnell, D. Kufe
Harvard Medical School, Boston, MA
We are currently completing a study examining the nature of
humoral and cellular immune reconstitution in patients with
advanced breast cancer who are undergoing high-dose chemother-
apy with stem cell rescue. Twenty patients have been enrolled, 11
with at least 3 months of follow-up. With one exception, all
patients experienced inversion of T4/T8 ratios posttransplant with
recovery incomplete at 6 months. Before undergoing high-dose
chemotherapy, all patients had intact DTH responses to candida.
This response was uniformly lost after transplantation except in a
single patient, and most patients remained anergic for 
more than 3 months. A majority of patients demonstrated active T
cell proliferation in response to PHA and allogeneic monocytes,
which was lost posttransplant. Recovery was seen no earlier than 3
months. Dendritic cells were generated from adherent PBMC
posttransplant and cultured in GM-CSF and IL-4. In contrast to
the profound functional deﬁciencies seen with the T cell popula-
tion, DC displayed characteristic phenotype and were potent
inducers of allogeneic T cell proliferation. This ongoing study
demonstrated signiﬁcant dysfunction in cellular immunity for at
least 3 months after stem cell transplantation in patients with
advanced breast cancer. This information is crucial in planning
posttransplant immunotherapeutic strategies.
ENGINEERED GRAFT CHARACTERISTICS CAN BE TAILORED BY THE
CHOICE OF STEM CELL SELECTOR
H. Atkins, M. Halpenny, P. Birch, C. Bredeson, I. Bence-Bruckler, 
S. McDiarmid, A. Guilivi, L. Huebsch
Blood and Marrow Transplant Program, Ottawa General Hospital,
Ottawa, Ontario, Canada
For every cell separation procedure there is a balance between efﬁ-
cient stem cell recovery and the depletion of unwanted cells. Clinical
circumstances may favor one of these two variables. This study was
designed to elucidate the operating characteristics of two commercially
available stem cell separation machines.
G-CSF–stimulaled peripheral blood stem cell collections or G-
CSF–stimulated bone marrow harvests obtained from normal donors
were processed using the Isolex SA (Baxter, IL) or the Ceprate SC
(Cellpro, WA). CD34 stem cells and CD3 lymphocytes were mea-
sured by ﬂow cytometry following staining with ﬂuorescently labeled
monoclonal antibodies.
The average percent of CD34 recovery after processing on the
Ceprate was 51 
 25% (n35). The average percent of CD34 recovery
after processing on the Isolex was 37 
 22% (n14). There was a trend
to higher CD34 recoveries on products processed on the Ceprate (p 
0.07). The average T cell depletion after processing on the Ceprate was
2.94 
 0.46 log (n34), while the average T cell depletion after pro-
cessing on the Isolex was 3.35 
 0.51 log (n14). T cell depletion by
the Isolex was signiﬁcantly better (p  0.009) than by the Ceprate. Both
machines performed better on PBSC than on bone marrow.
There is a trend for lower CD34 recovery but signiﬁcantly greater
depletion of uwanted cell populations by the Isolex SA compared with the
Ceprate SC. In situations in which depletion of non–stem cells is impor-
tant, the former separator may be preferred. In situations in which CD34
recovery is critical, the use of the latter separator may be optimal. Inherent
in both machines is the variability in processing results as evidenced by the
large standard deviations. A better understanding of the reasons for the
operating variability would improve the reliability of these machines.
ABH INCOMPATIBILITY AS A PROGNOSTIC FACTOR IN ALLOGENEIC
STEM CELL TRANSPLANTATION
R.J. Benjamin, S. McGurk; M.S. Ralston; W.H. Churchill, JH Antin
Brigham and Womens Hospital, Boston, MA
Allogeneic stem cell transplantation across ABH barriers may
result in a variety of immune-mediated disorders, ranging from
hemolysis to RBC aplasia. These complications either respond to
supportive care or may be readily avoided and have not been asso-
ciated with a poor outcome. We therefore adopted a policy in
ABH-incompatible transplantation that incorporated minimal
manipulation of the recipient and the graft, or of transfused blood
components after transplantation.
A retrospective survival analysis of a cohort of 292 allogeneic
transplantation recipients, including 112 CML and 90 AML or
MDS patients, was performed.
Kaplan-Meier survival statistics revealed a signiﬁcantly reduced
survival in a subgroup of ABH-incompatible transplantation recipi-
ents. Patients with primary or secondary AML or MDS, receiving
non–T cell-depleted grafts from living related donors and
methotrexate/cyclosporine GVHD prophylaxis, had a 2.5-fold
greater risk of death within 100 days of transplantation than com-
parable patients with ABH-compatible grafts (p  0.0002). Death
was due to regimen-related toxicity.
These data suggest that ABH incompatibility is a significant
prognostic risk factor in allogeneic stem cell transplantation in our
clinical setting and emphasize the need to constantly reassess the
potential adverse effects of changes in transfusion practice.
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THE EFFICACY AND SAFETY OF MYCOPHENOLATE MOFETIL IN THE
TREATMENT OF ACUTE AND CHRONIC GVHD IN BONE MARROW
TRANSPLANT PATIENTS
W.I. Blau; N. Basara, M.G. Kiehl, A.A. Fauser
Department of Bone Marrow Transplantation, Idar-Oberstein, Germany
Mycophenolate mofetil (MMF) is a well known inhibitor of T- and
B-cell proliferation and well established in the prophylaxis of rejection
in cadaveric renal transplantation. In an ongoing study, we investigate
the efﬁcacy and safety of MMF in the treatment of acute and chronic
GVHD in patients after BMT or PBSCT for hematological malignan-
cies. Thirty-ﬁve patients (ages 17–54) with acute GVHD (n24) and
chronic GVHD (n11) were treated with 2g MMF daily in addition to
CsA and prednisolone, whereas 21 of the control group (acute GVHD
n14; chronic GVHD n7) were treated with CsA and prednisolone
only. The prophylaxis of acute GVHD consisted of a combination of
MTX, CsA, and prednisolone. Overall grade improvement of acute
GVHD was found in 18 of 24 patients (75%) treated with MMF,
whereas in the control group only 5 of 14 patients (29%) responded (p
 0.001). Nineteen of 20 patients with skin involvement and 7 of 11
patients with liver involvement of acute GvHD showed improvement.
This is signiﬁcantly different from the control group (p  0.009 and p
 0.006, respectively). MMF therapy in the treatment of chronic
GVHD lead to moderate improvement in 4 of 8 patients with limited
chronic GVHD. Prednisolone therapy in the treatment of chronic
GVHD did not lead to improvement of extensive or limited GVHD
except in one patient. The most common hematological adverse events
of MMF were leukocytopenia (n9), anemia (n9), and thrombocy-
topenia (n9). These adverse events were not severe and did not
require the discontinuation of MMF. Moreover, 33% of the control
group developed severe adverse effects due to prednisolone therapy
(e.g., steroid induced diabetes, osteoporosis, acute pancreatitis, acute
psychosis), which were not observed in MMF-treated patients. In addi-
tion, MMF therapy resulted in a signiﬁcant dose reduction of pred-
nisolone for the treatment of GVHD. From this preliminary data, we
conclude that MMF might be beneﬁcial for the treatment of acute and
chronic GVHD in bone marrow transplant recipients. A study update
will be presented.
THE INCIDENCE AND RISK FACTORS FOR DEVELOPING LATE PNEU-
MONIA FOLLOWING AUTOLOGOUS AND ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION
C.S. Chen, K. Seidel, M. Boeckh, J. Clark, M. Siadak, M.E.D. Flowers,
K.M. Sullivan
Fred Hutchinson Cancer Research Center and the University of Wash-
ington, Seattle, WA
The incidence and risk factors for late pneumonia following transplanta-
tion are largely unknown. A total of 1462 patients who received transplants
in Seattle and were prospectively followed after fulﬁlling home discharge
criteria were included in this study. The median times of discharge were 99
days (range 15–359), 95 days (12–250), and 50 days (11–268) posttransplant
among unrelated, allogeneic, and autologous/twin transplants, respectively.
A total of 389 patients subsequently developed at least one episode of pneu-
monia during a median follow-up of 2 (range 0.01–5) years after home dis-
charge. Two hundred sixteen cases (55.5%) developed pneumonia without
a history of extensive chronic GVHD. Known etiologies of ﬁrst pneumonia
included idiopathic pneumonia syndrome (8%), bacterial (8%), viral (10%),
fungal (7%), PCP (5%), and multiple organisms (4%). Survival rates at 1
year after pneumonia were low in patients diagnosed with multiple organ-
isms (17%), fungal (23%), or viral (35%) etiologies, but were higher in
those with PCP (48%), idiopathic (55%), or bacterial (61%) pneumonias.
In 227 cases (58%), patients were empirically treated without a tissue diag-
nosis. These clinical pneumonia patients had a 1 year survival rate of 66%.
Multivariate analysis of pneumonia development showed independent risk
factors of patient age (RR 0.5 for 20 years, 1.2 for 40 years), type of
donor (RR 1.9 for unrelated and 0.3 for autologous/twin), TBI (RR 1.8 for
1300 cGY) and chronic GVHD (RR 1.3 for extensive group). The prima-
ry underlying disease, patient and donor CMV serostatus, and history of
acute GVHD were not statistically associated with increased or decreased
risk. The cumulative incidences of pneumonia by donor type at 1 and 4
years after discharge were 14% and 22% (auto/twin), 22% and 33% (allo),
and 28% and 46% (unrelated). In conclusion, pneumonia poses signiﬁcant
morbidity and mortality over an extended period after transplantation and
requires continued long term follow-up and appropriate prophylaxis.
BLISTERS RESULTING FROM HUMAN HERPESVIRUS-6 IN ALLOGENEIC
MARROW GRAFT RECIPIENTS
C. Boldt, C. Bredeson, I. Bence-Bruckler, L. Huebsch, F. Diaz-Mitoma,
H. Atkins
University of Ottawa, Ottawa, Ontario, Canada
The clinical spectrum of human herpesvirus-6 (HHV-6) disease
in BMT recipients is still being clariﬁed. We describe 2 cases of
blistering skin rashes caused by HHV-6. This complication of
HHV-6 has not been previously described.
CASE 1: A 54-year-old woman received an allogeneic bone mar-
row transplant from an HLA-identical sibling for AML. Day 53 she
was well, but on her thigh had a 11 cm blister, which was aspirat-
ed and positive for HHV-6 DNA by PCR. Additional discrete blis-
ters developed in the region and resolved spontaneously over the
next month. Following this, she developed grade I cutaneous
GVHD. All CMV surveillance studies of blood and urine were neg-
ative. At day 90, she was well with a normal performance status.
CASE 2: A 49-year-old woman received a haploidentical bone
marrow transplant for RAEB-T. She developed cutaneous grade II
GVHD, requiring methylprednisolone. On day 31, a 55 cm blis-
ter developed on her foot. Fluid aspirated from the blister was posi-
tive for HHV-6 DNA by PCR. She had persistent fever, poor graft
function, and HHV-6 DNA was found in her blood repeatedly
from day 24 to day 45. CMV DNA was also detected in her blood
day 37. Therapy with ganciclovir was initiated and was followed by
complete clinical improvement.
These two cases illustrate that HHV-6 can cause blistering skin
rashes in the early posttransplant period.
ENGRAFTMENT OF HUMAN HEMATOPOIETIC STEM CELLS IN
NOD/SCID MICE IMPROVES WITH USE OF ASIALO-GM1 ANTIBODY
P.D. Conrad, P.A. Stephen, G. Emerson
Children’s Hospital of Philadelphia, Philadelphia, PA
NOD/SCID mice have been used to assay primitive human
hematopoietic stem cells. Human cells are inserted via tail vein
injection into the sublethally irradiated mouse, and the engraftment
assessed at various time points. However, NOD/SCID transplanta-
tion experiments in many labs have shown low-level and erratic
results. We had previously found only low (9%) spleen cell
engraftment, and no peripheral blood (PB) engraftment using stan-
dard 350cGy/107 umbilical cord blood (UCB) mononuclear cell
(MNC) transplants. We have now repeated the experiment using
107 UCB MNCs/mouse, varying radiation dose (100–300 cGy) and
adding intraperitoneal injection of 675 mcg of asialo-GM1 antibody
(anti-NK cell) on days 0, 8, and 14. PB was assayed at day 30.
Results revealed striking levels of engraftment in one mouse and
evidence of human engraftment in each of the four others assayed.
In one mouse receiving 100cGy, 25% of peripheral MNC were
CD45. The average level of engraftment was 2.4% (300cGy),
0.48% (200cGy), and 12.6% CD45 (100cGy). These results indi-
cate that there may be residual NK cell function inhibiting human
engraftment in these mice and the provision of a blocking NK anti-
body may lead to improved engraftment. This in turn may lead to
improved in vivo assay techniques for early human stem cells.
